December 3, 2021

Dumbflashgames

The travel folks

Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

3 min read

Press Launch



up to date: Nov 12, 2020


Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, declared today that the to start with individual has been efficiently dosed in a Section 2, 20-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Demo of EPX-one hundred as Adjunctive Therapy in Little ones with Dravet Syndrome. This study will appraise the efficacy and basic safety of EPX-one hundred in youngsters suffering from Dravet Syndrome. The Company is in the middle of recruiting 24 sufferers to complete the review. In depth review and web site details is available at www.clinicaltrials.gov and dravetfoundation.org.

Dravet Syndrome is a scarce, catastrophic, lifelong kind of epilepsy which commences in the to start with calendar year of life with regular or extended seizures. Mental disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are usually observed as the disorder progresses. People put up with from life-threatening seizures that simply cannot be adequately controlled with available prescription drugs and face an increased hazard of SUDEP (Sudden Unexplained Demise in Epilepsy), seizure-related accidents these kinds of as drowning, or bacterial infections.

Dr. Hahn-Jun Lee, M.Sc., Ph.D., President and CEO of Epygenix Therapeutics, Inc. stated, “We are pretty psyched to announce that first individual has been efficiently dosed in our trial. 1st individual dosing is an incredibly essential clinical milestone of EPX-one hundred, as this is the very important to start with move to appraise the efficacy and basic safety of EPX-one hundred in sufferers. We have designed terrific efforts so considerably and will consistently work to obtain meaningful clinical results for Dravet sufferers.”

Dr. Scott C. Baraban, Ph.D., Professor & William K. Bowes Jr. Endowed Chair in Neuroscience Research at UCSF and Chair of the Scientific Advisory Board at Epygenix Therapeutics, Inc. issued a joint remark that “Starting the method of assessing EPX-one hundred in Dravet Syndrome sufferers is the culmination of a pretty remarkable journey from the ‘aquarium’ to the ‘bedside’. We are optimistic that Epygenix medications will offer you a secure and productive treatment choice for these youngsters.”

Alex Yang, J.D., LLM, President and CEO of Mstone Partners Hong Kong and Chair of the Board at Epygenix Therapeutics also stated that “Supplied our sturdy science track record and excellent basic safety profile, we are cautiously optimistic that EPX-one hundred will produce fantastic results in this trial and get a further move in the direction of the greatest-in-class drug for refractory epilepsies.”   

About Epygenix Therapeutics, Inc.

 

Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company centered on identifying and developing medications to deal with scarce and intractable genetic epilepsy in childhood, these kinds of as Dravet Syndrome. Epygenix is currently centered on developing EPX-one hundred, -two hundred, and -300. These candidates abolish convulsive habits and electrographic seizure exercise and were being found in a zebrafish Dravet Syndrome product which mimics the human pathology and confirmed its validity by the human efficacy with EPX-two hundred and -300. For additional details, remember to pay a visit to www.epygenix.com.

 

 About EPX-one hundred

 

EPX-one hundred is a to start with-generation antihistamine and discovered to be a impressive suppressor of spontaneous convulsive habits and electrographic seizures in zebrafish models for Dravet Syndrome. Its antiepileptic action, even so, is not through a histaminergic mechanism of motion, but by using modulation of serotonin (5HT) signaling pathways. Its basic safety has been confirmed with the finished Section I, Placebo-Controlled, Double-Blind, 2-Interval Examine to evaluate basic safety and pharmacokinetics of escalating solitary and numerous oral doses of EPX-one hundred in fasting healthy topics and subsequent a large-fat food. 

 

Media Make contact with

Hahn-Jun Lee, M.Sc., Ph.D.
201-724-1786
[email protected]

Resource: Epygenix Therapeutics, Inc.

Dumbflashgames.com All rights reserved. | Newsphere by AF themes.